http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Applied Therapeutics Provides FDA Update on PDUFA Target Action Date for Govorestat for the Treatment of Classic Galactosemia
-
Applied Therapeutics Reports Fourth Quarter and Year-end 2023 Financial Results
-
Applied Therapeutics (APLT) Announces FDA Acceptance and Priority Review of New Drug Application for Govorestat for the Treatment of Classic Galactosemia
-
Applied Therapeutics (APLT) Announces $100 Million Private Placement
-
Applied Therapeutics Announces $100 Million Private Placement
-
Applied Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Govorestat for the Treatment of Classic Galactosemia
-
Applied Therapeutics (APLT) Announces Positive Results from 12-month Interim Analysis of Govorestat (AT-007) in the Ongoing INSPIRE Phase 3 Trial in SORD Deficiency
-
Applied Therapeutics Announces Positive Results from 12-month Interim Analysis of Govorestat (AT-007) in the Ongoing INSPIRE Phase 3 Trial in Sorbitol Dehydrogenase (SORD) Deficiency
-
Applied Therapeutics (APLT) Reports Topline Results from the ARISE-HF Phase 3 Study of AT-001
-
Applied Therapeutics Announces Topline Results from the ARISE-HF Phase 3 Study of AT-001 in Diabetic Cardiomyopathy
-
Applied Therapeutics Inc. (APLT) Announces MAA Validation and NDA Submission of Govorestat
-
Applied Therapeutics Announces MAA Validation and NDA Submission of Govorestat (AT-007) for Treatment of Classic Galactosemia
-
Applied Therapeutics Reports Third Quarter 2023 Financial Results
-
Applied Therapeutics to Present at the UBS Biopharma Conference 2023
-
Applied Therapeutics to Host Diabetic Cardiomyopathy Expert Forum with Key Opinion Leaders on Tuesday, November 7
-
Applied Therapeutics to Present Baseline Data from Phase 3 ARISE-HF Study Evaluating AT-001 at the 2023 EASD Annual Meeting
-
Applied Therapeutics Inc. (APLT) Announces Successful Pre-NDA Meeting with the FDA and Confirms Plans to Submit NDA for Govorestat (AT-007)
-
Applied Therapeutics Announces Successful Pre-NDA Meeting with the FDA and Confirms Plans to Submit NDA for Govorestat (AT-007) for Treatment of Classic Galactosemia to FDA in Q4 2023
-
Applied Therapeutics Reports Second Quarter 2023 Financial Results
-
Applied Therapeutics (APLT) Provides Regulatory Update on Galactosemia Program
-
Applied Therapeutics Provides Regulatory Update on Galactosemia Program
-
Applied Therapeutics to Present Baseline Data on the Phase 3 ARISE-HF Study in Diabetic Cardiomyopathy at the 2023 Annual Meeting of the American Diabetes Association
-
Applied Therapeutics to Present Data on AT-007 (Govorestat) Treatment in SORD Deficiency at the 2023 Annual Meeting of the Peripheral Nerve Society
-
Applied Therapeutics (APLT) Receives Orphan Medicinal Product Designation in Europe for Govorestat
-
Govorestat (AT-007) Receives Orphan Medicinal Product Designation from the EMA for Treatment of SORD Deficiency
-
Applied Therapeutics Reports First Quarter 2023 Financial Results
-
Applied Therapeutics Inc. (APLT) Announces Clinical Benefit of Govorestat in ACTION-Galactosemia Kids Trial, Plans to Meet with FDA
-
Applied Therapeutics Inc. (APLT) Announces $30 Million Private Placement of Equity
-
Applied Therapeutics, Inc. Announces $30 Million Private Placement of Equity
-
Applied Therapeutics, Inc. Announces $30 Million Private Placement of Equity
-
Applied Therapeutics Announces Clinical Benefit of Govorestat (AT-007) in ACTION-Galactosemia Kids Trial; Company Plans to Meet with FDA Regarding Potential NDA Submission
-
Applied Therapeutics Announces Clinical Benefit of Govorestat (AT-007) in ACTION-Galactosemia Kids Trial; Company Plans to Meet with FDA Regarding Potential NDA Submission
-
Applied Therapeutics Reports Fourth Quarter and Year-end 2022 Financial Results
-
Applied Therapeutics Reports Fourth Quarter and Year-end 2022 Financial Results
-
Applied Therapeutics to Present at the Cowen 43rd Annual Health Care Conference
-
Applied Therapeutics to Present at the Cowen 43rd Annual Health Care Conference
-
Applied Therapeutics Inc. (APLT) Announces Positive Sorbitol Reduction Data From the Ongoing Phase 3 INSPIRE Trial
-
Applied Therapeutics Announces Positive Sorbitol Reduction Data From the Ongoing Phase 3 INSPIRE Trial in Sorbitol Dehydrogenase (SORD) Deficiency
-
Applied Therapeutics Announces Positive Sorbitol Reduction Data From the Ongoing Phase 3 INSPIRE Trial in Sorbitol Dehydrogenase (SORD) Deficiency
-
Applied Therapeutics to Present at the SVB Securities Global Biopharma Conference
-
Applied Therapeutics to Present at the SVB Securities Global Biopharma Conference
-
Applied Therapeutics Announces Partnership with Advanz Pharma for Commercialization of AT-007 (Govorestat) in Europe
-
Applied Therapeutics Announces Partnership with Advanz Pharma for Commercialization of AT-007 (Govorestat) in Europe
-
Applied Therapeutics Reports Third Quarter 2022 Financial Results
-
Applied Therapeutics Reports Third Quarter 2022 Financial Results
-
Applied Therapeutics Announces Multiple Data Presentations at the American Heart Association Scientific Sessions November 5-7, 2022
-
Applied Therapeutics Announces Multiple Data Presentations at the American Heart Association Scientific Sessions November 5-7, 2022
-
Applied Therapeutics Announces Full Enrollment in the Registrational Phase 3 ARISE-HF Trial of AT-001 in Diabetic Cardiomyopathy
-
Applied Therapeutics Announces Full Enrollment in the Registrational Phase 3 ARISE-HF Trial of AT-001 in Diabetic Cardiomyopathy
-
Applied Therapeutics Inc. (APLT) Reports Positive Data Trend in AT-007
